Psoriasis Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

Published February 2, 2023

DelveInsight’s “Psoriasis Pipeline Insight 2023” report provides comprehensive global coverage of available, marketed, and pipeline Psoriasis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Psoriasis pipeline domain.

Psoriasis Overview

Psoriasis is a skin disease which is caused by genetic, environmental and immunological factors. Psoriasis is diagnosed in almost 2% of the world population. Psoriasis causes red and scaly skin which can be differentiated from normal skin.

Some of the key takeaways from the Psoriasis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Psoriasis treatment therapies with a considerable amount of success over the years. Psoriasis Key players such as – Luye pharma group,Cantagria, Azora Therapeutics, Boston Pharmaceuticals, Eli Lilly and Company,Escalier Biosciences,DelArrivo, Inc., Aldeyra Therapeutics, Aurigene Discovery Technologies,AbbVie,Amgen,Akeso Biopharma,CanFite Biopharma , and others, are developing therapies for the Psoriasis treatment
• Psoriasis Emerging therapies such as – TS1808,CAN 10,AT193,BOS-475,LY3361237,ESR114, DLX1055-DMP,ADX-629,AUR-101,Cedirogant, ABP 654, AK-101,Piclidenoson , and others are expected to have a significant impact on the Psoriasis market in the coming years.

Discover more about the emerging Psoriasis drugs @ Psoriasis Treatment Drugs

Emerging Psoriasis Drugs Under Different Phases of Clinical Development Include:

• TS1808- Luye pharma group
• CAN 10- Cantagria
• AT193- Azora Therapeutics
• BOS-475- Boston Pharmaceuticals
• LY3361237- Eli Lilly and Company
• ESR114- Escalier Biosciences
• DLX1055-DMP – DelArrivo, Inc.
• ADX-629- Aldeyra Therapeutics
• AUR-101- Aurigene Discovery Technologies
• Cedirogant- AbbVie
• ABP 654- Amgen
• AK-101- Akeso Biopharma
• Piclidenoson- CanFite Biopharma

Psoriasis Pipeline Analysis:

The Psoriasis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the Psoriasis treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriasis Treatment.
• Psoriasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Psoriasis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Psoriasis Market Drivers

• Increasing geriatric population
• Huge pipeline of biosimilar and biologics
• Favourable reimbursement policies

Psoriasis Market Barriers

• High cost of treatment
• Side effects of Psoriasis medication.

Find out more about the Psoriasis treatment options in development @ Psoriasis Clinical Trials

Scope of Psoriasis Pipeline Drug Insight

• Coverage: Global
• Key Psoriasis Companies: Luye pharma group,Cantagria, Azora Therapeutics, Boston Pharmaceuticals, Eli Lilly and Company,Escalier Biosciences,DelArrivo, Inc., Aldeyra Therapeutics, Aurigene Discovery Technologies,AbbVie,Amgen,Akeso Biopharma,CanFite Biopharma, and others
• Key Psoriasis Therapies: TS1808, CAN 10, AT193, BOS-475, LY3361237, ESR114, DLX1055-DMP, ADX-629, AUR-101, Cedirogant, ABP 654, AK-101, Piclidenoson , and others
• Psoriasis Therapeutic Assessment: Psoriasis current marketed and Psoriasis emerging therapies
• Psoriasis Market Dynamics: Psoriasis market drivers and Psoriasis market barriers

Table of Contents

1. Introduction
2. Executive Summary
3. Psoriasis Overview
4. Psoriasis Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Psoriasis Therapeutic Assessment
11. Psoriasis Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Psoriasis Unmet Needs
14. Psoriasis Market Drivers and Psoriasis Market Barriers
15. Appendix
16. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

Contact Us

Navdha Goel